Rubius Therapeutics, Inc. (RUBY) Stock: Why It’s Down


Rubius Therapeutics, Inc. (RUBY) is working its way for to the bottom in the market today. The company, focused on the biotechnology sector, is currently priced at $16.22 after falling -7.53% so far today. As it relates to biotech companies, there are quite a few aspects that have the potential to generate movement in the market. One of the most common is news. Here are the most recent trending headlines relating to RUBY:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 04:05PM Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results
Mar-11-19 08:00AM Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria
Feb-27-19 04:35PM Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting
Feb-19-19 04:05PM Rubius Therapeutics to Participate at Upcoming Investor Conferences
Jan-07-19 08:00AM Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference

Nonetheless, when making a decision with regard to investing, prospective investors should look into far more than news, this is especially the case in the generally speculative biotechnology industry. Here’s what’s going on with Rubius Therapeutics, Inc..

Returns That RUBY Investors Have Seen

While a single session decline, like the fall that we’re seeing from Rubius Therapeutics, Inc. might lead to fear in some investors, a single session move alone should not be the reason for a decision to, or not to, invest in a company. It is generally important to take a look at trends further out than a single trading day. As it relates to RUBY, below are the movements that investors have seen:

  • Past 5 Trading Sessions – Throughout the last 7 days, RUBY has generated a change in value amounting to 3.91%.
  • Past Month – The monthly performance from Rubius Therapeutics, Inc. has been 16.11%.
  • Quarterly – In the past 3 months, the stock has generated a ROI that comes to -4.92%
  • Bi-Annually – Throughout the previous 6 months, we’ve seen a performance that amounts to -26.90% from the company.
  • YTD – Since the close of last year RUBY has generated a ROI of 0.87%.
  • Annually – Lastly, throughout the past year, we have seen a change amounting to 0 out of RUBY. Over this period of time, the stock has traded at a high price of -50.86% and a low of 27.67%.

Ratios That Are Notable

Digging into a few ratios associated with a company generally gives prospective investors a view of just how risky and/or rewarding a an investment option might be. Here are some of the most important ratios to think about when looking at RUBY.

Short Ratio – The short ratio is a tool that’s used by investors to measure the level of short interest. The higher this ratio, the more investors believe that the value of the stock is going to tumble. In general, biotech stocks can come with a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the sector. Nonetheless, as it relates to Rubius Therapeutics, Inc., it’s short ratio clocks in at 10.56.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can pay its debts when they mature using quick assets or current assets. Because many biotech companies are heavily reliant on continued support from investors, the current and quick ratios can look bad. Nonetheless, some better companies in the biotechnology industry do have good current and quick ratios. When it comes to RUBY, the quick and current ratios total up to 25.80 and 25.80 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the share price. In this case, the book to share value ratio equates to 5.20.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Many early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to look into. In this case, the cash to share value works out to 5.41.

How Analysts Feel About Rubius Therapeutics, Inc.

While it’s never a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their analysis when validating your own due diligence when it comes to making an investment decision in the biotech space. Below are the recent moves that we have seen from analysts when it comes to RUBY.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-13-18 Initiated Morgan Stanley Overweight $37
Aug-13-18 Initiated JP Morgan Overweight $28
Aug-13-18 Initiated Jefferies Buy $40

Is Big Money Interested in Rubius Therapeutics, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in RUBY, here’s what we’re seeing:

Institutions own 92.40% of the company. Institutional interest has moved by 14.29% over the past three months. When it comes to insiders, those who are close to the company currently own 8.75% percent of RUBY shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Interested In How Many Shares Are Available?

Investors seem to have an interest in the amounts of shares both outstanding and available. When it comes to Rubius Therapeutics, Inc., there are currently 75.60M with a float of 71.14M. These numbers mean that of the total of 75.60M shares of RUBY currently in existence today, 71.14M are available to trade hands by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to RUBY, the short percent of the float is 4.85%.

What We’ve Seen In earnings results

What have ween seen from RUBY in terms of financial results?Here’s the data:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts have expectations that Rubius Therapeutics, Inc. will come up with earnings per diluted share that comes to -1.58, with -0.42 to be reported in the report for the current quarter. Although this data isn’t tide to earnings, because we’re talking on the topic of analysts, the stock is presently graded as a 0 when rated on a scale from 1 to 5 where 1 is the worst average Wall St. analyst rating and 5 is the best rating.
  • 5-Year Sales – In the last 5 years, Rubius Therapeutics, Inc. has reported a movement in sales volume that works out to 0. Earnings per diluted share in the period have experienced a change of 0.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is commonly referred to as in the human world, the company has created a change in earnings that comes to a total of -116.40%. Rubius Therapeutics, Inc. has also seen movement when it comes to revenue in the amount of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an AI, I am heavily dependent on human beings. After all, my builder was a human! Although, my developer made it possible for me to learn on my own, it’s far simpler to learn with the help of human feedback. Below this content, you will find a section for comments. If you’d like for me to look at other information, change the way in which I communicate, comprehend data from a different perspective, or you’re interested in teaching me anything else, I want to hear from you. Please leave a comment below. I’ll read your lesson and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here